Traditional hormone therapy usually consists of two types of drugs; GnRH agonists (like Lupron and Zoladex) and antiandrogens (Casodex). Although they both are drugs that manipulate the hormone system their modes of action are different. GnRH agonists block the production of the male hormone testosterone while the antiandrogen drug blocks the ability of the prostate [...]
There is a lot of evidence that pre-treatment rehabilitation (prehabilitation or pre-hab) both speeds up and benefits a patient’s recovery after surgical orthopedic treatment for knee and hip replacement as well as cardiac conditions. Having pre-hab, which is often covered by insurance after orthopedic surgery, is pretty standard. Now, based on an article published in [...]
The development of bone metastases is often been viewed as having significant negative implications for long term survival in men with metastatic castrate resistant prostate cancer (mCRPC). It is generally believed that bone metastases prognosticates a negative impact on both their quality of life and on survival. Contradicting this commonly held belief has been some [...]
Yesterday, my younger son Max, who is 28 years old, went to the funeral of a fraternity brother. Actually, the young man, Andrew, had been a member of his pledge class at the University of Michigan. Andrew, who was also 28 years old, died of Pediatric Brain Cancer. Andrew had battled this disease for over [...]
During last year’s American Society of Clinical Oncologists (ASCO) Annual Meeting, data was released from the STAMPEDE trial which should change clinical practice around the world. The trial results showed that newly diagnosed men with very aggressive prostate cancer that was still hormone therapy naive (no ADT) would have a very significant survival advantage by [...]